T1	Participants 577 628	A total of 24 patients were recruited to the study;
T2	Participants 629 692	ten received cyclosporin with blood transfusions (BT) (group 1)
T3	Participants 694 724	14 received BT alone (group 2)
T4	Participants 726 785	Anti-HLA antibodies developed in 3 of 9 patients in group 1
T5	Participants 790 817	8 of 12 patients in group 2
